非霍奇金淋巴瘤的代谢异质性研究  

Metabolic heterogeneity in non-Hodgkin lymphoma

作　　者：徐珍珍 曹蓓[1] 费菲 李娟[1] XU Zhenzhen;CAO Bei;FEI Fei;LI Juan(Department of PhaseⅠClinical Trials Unit,Nanjing Drum Tower Hospital,Affiliated Hospitalof Medical School,Nanjing University,Nanjing,210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院Ⅰ期临床试验研究中心,南京210008

出　　处：《临床血液学杂志》2025年第3期212-219,共8页Journal of Clinical Hematology

基　　金：国家自然科学基金项目(No:82304609);中央高校基本科研业务专项资金(No:3332023097)。

摘　　要：目的:探索非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)中弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者与其他类型NHL患者的临床、实验室检查的特征和代谢差异。方法:2018年8月—2023年6月在南京大学医学院附属鼓楼医院收取新鲜组织97例,其中健康人淋巴结增生组织26例,NHL淋巴瘤组织71例。该研究对71例NHL患者的临床资料及实验室特征进行了回顾性分析。同时采用气相色谱-质谱分析(GC/MS)方法,对健康人淋巴结增生组织及NHL淋巴瘤组织进行了非靶向代谢组学分析,并对NHL及DLBCL、其他类型B细胞非霍奇金淋巴瘤(B-cell non-Hodgkin lymphoma,B-NHL)、T细胞非霍奇金淋巴瘤(T-cell non-Hodgkin lymphoma,T-NHL)与健康人之间的具体差异代谢物进行了通路富集分析。结果:71例NHL患者淋巴瘤组织与26例健康人淋巴结增生组织2组间的年龄(P=0.439)及性别(P=0.069)分布差异无统计学意义。71例NHL患者的临床及实验室特征回顾性分析结果显示:DLBCL患者与其他类型B-NHL及TNHL患者之间在年龄、性别、分期、国际预后指数(International Prognostic Index,IPI)评分等方面差异无统计学意义,但DLBCL较其他类型B-NHL的治疗效果及生存情况不佳。DLBCL与其他类型B-NHL和T-NHL患者比较,除C反应蛋白水平差异有统计学意义外,其余血常规及生化指标亦差异无统计学意义。与其他类型B-NHL比较,DLBCL易出现CD30、MYC、BCL6、MUM1和Ki67的阳性表达,两者之间差异有统计学意义(P<0.05);与T-NHL比较,DLBCL易出现CD79a、MYC、BCL2和MUM1的阳性表达,两者之间差异有统计学意义(P<0.05)。非靶向代谢组学分析发现:NHL患者与健康人存在明显的代谢差异,且DLBCL与其他类型B-NHL和T-NHL之间也存在明显的代谢差异。与健康人比较,DLBCL组织中有12个上调的差异代谢物,主要富集在丙酮酸、柠檬酸循环及甘油脂类代谢途径上;其他类型B-NHL组织中共有19个差异代谢Objective:To explore the features of clinical and laboratory tests,and metabolic differences between patients with diffuse large B-cell lymphoma(DLBCL)in non-Hodgkin lymphoma(NHL)and patients with other types of NHL.Methods:From August 2018to June 2023,97fresh tissues were collected from Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,including 26healthy lymph node hyperplasia tissues and 71NHL lymphoma tissues.The clinical data and laboratory features of 71patients with NHL were retrospectively analyzed.Meanwhile,the non-targeted metabolomics of hyperplasia lymph node tissues and NHL lymphoma tissues were analyzed by gas chromatography-mass spectrometry(GC/MS),and the pathways enrichment between NHL and DLBCL,other types of NHL and healthy people were analyzed.Results:There was no significant difference in age(P=0.439)and sex(P=0.069)between 71NHL patients and 26 healthy subjects.Retrospective analysis of clinical and laboratory characteristics of 71NHL patients showed that:there was no statistical difference in age,sex,stage,IPI score between patients with DLBCL and patients with other types of B-cell non-Hodgkin lymphoma(B-NHL)and T-cell non-Hodgkin lymphoma(T-NHL),but DLBCL had poor therapeutic effect and survival compared with other types of B-NHL.Compared with other types of BNHL and T-NHL patients,DLBCL showed no statistical difference in blood routine and biochemical indexes except for C-reactive protein level.Compared with other types of B-NHL,DLBCL was more likely to show positive expressions of CD30,MYC,BCL6,MUM1and Ki67,and the difference was statistically significant(P<0.05).Compared with T-NHL,DLBCL was more likely to show positive expressions of CD79a,MYC,BCL2and MUM1,and the differences between the two were statistically significant(P<0.05).Non-targeted metabolomic analysis revealed significant metabolic differences between tissues of NHL patients and healthy individuals,as well as between DLBCL and other types of B-NHL and T-NHL.Compared with healthy people,th

关 键 词：非霍奇金淋巴瘤 弥漫大B细胞淋巴瘤 代谢组学分析 代谢异质性 

分 类 号：R733.1[医药卫生—肿瘤]